Personalis (NASDAQ:PSNL) CFO Aaron Tachibana Sells 2,931 Shares of Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 2,931 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $16.22, for a total value of $47,540.82. Following the sale, the chief financial officer owned 195,902 shares in the company, valued at approximately $3,177,530.44. This represents a 1.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Aaron Tachibana also recently made the following trade(s):

• On Monday, June 29th, Aaron Tachibana sold 4,982 shares of Personalis stock. The shares were sold at an average price of $14.00, for a total transaction of $69,748.00.
• On Friday, June 26th, Aaron Tachibana sold 51,251 shares of Personalis stock. The shares were sold at an average price of $13.18, for a total transaction of $675,488.18.

Personalis Stock Performance

Shares of PSNL stock opened at $16.36 on Wednesday. Personalis, Inc. has a 52-week low of $4.95 and a 52-week high of $18.89. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of -15.01 and a beta of 2.31. The firm’s 50-day moving average is $15.09 and its 200-day moving average is $10.94.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). The business had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. Sell-side analysts predict that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Institutional Trading of Personalis

A number of institutional investors have recently modified their holdings of the stock. Tidal Investments LLC acquired a new position in Personalis in the second quarter valued at about $1,146,000. WINTON GROUP Ltd acquired a new stake in Personalis during the second quarter worth about $496,000. Engineers Gate Manager LP bought a new position in Personalis in the 2nd quarter valued at about $1,552,000. Squarepoint Ops LLC acquired a new position in shares of Personalis in the 2nd quarter valued at approximately $319,000. Finally, Arizona State Retirement System raised its position in shares of Personalis by 28.2% in the 2nd quarter. Arizona State Retirement System now owns 18,766 shares of the company’s stock valued at $251,000 after buying an additional 4,131 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. TD Cowen restated a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. Zacks Research upgraded Personalis from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Needham & Company LLC cut Personalis from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Lake Street Capital lowered Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective on the stock. in a report on Monday, July 20th. Finally, BTIG Research increased their price objective on Personalis from $11.00 to $16.25 and gave the stock a “buy” rating in a research report on Monday, July 20th. Four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $14.54.

About Personalis

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.